Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint
Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data.
Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data.
